NS 018

Drug Profile

NS 018

Alternative Names: NS-018

Latest Information Update: 09 Feb 2016

Price : $50

At a glance

  • Originator Nippon Shinyaku
  • Class Antineoplastics
  • Mechanism of Action Janus kinase-2 inhibitors; Src-Family kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Myelofibrosis
  • Discontinued Haematological disorders

Most Recent Events

  • 09 Feb 2016 Discontinued - Preclinical for Haematological disorders in Japan (PO)
  • 21 Sep 2015 Phase-I/II development is ongoing for Myelofibrosis in USA (PO)
  • 19 May 2014 Phase-I/II development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top